Key result
Preoperative levosimendan infusion significantly improved cardiac index (3.19 vs 2.24 L/min/m2, p<0.01) and reduced pulmonary capillary wedge pressure compared to placebo in patients undergoing OPCABG.
Why the study?
Does levosimendan pretreatment improve hemodynamics and clinical outcomes in patients with LVEF <30% undergoing OPCABG?
RCT (n=50)
Double-blind
Randomly assigned
No
Does levosimendan pretreatment improve hemodynamics and clinical outcomes in patients with LVEF <30% undergoing OPCABG?
Absolute Event Rate: 3.19% vs 2.24%
p-value: p=<0.01
Levosimendan pretreatment improves perioperative hemodynamics and reduces the need for inotropic and mechanical support in patients with severe LV dysfunction undergoing off-pump CABG.
No takes yet. Share an insight, caveat, or question.
Supports levosimendan pretreatment for hemodynamic optimization in low-LVEF OPCABG; extends RCT evidence to off-pump settings.
Shastri et al. (2014) conducted an RCT in Coronary artery disease with low left ventricular ejection fraction (<30%) requiring OPCABG (n=50). Levosimendan vs. Placebo was evaluated on Cardiac index at 24 hours post-infusion (T1) (p=<0.01). Preoperative levosimendan infusion significantly improved cardiac index (3.19 vs 2.24 L/min/m2, p<0.01) and reduced pulmonary capillary wedge pressure compared to placebo in patients undergoing OPCABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: